Purpose:　Emerging　evidence　shows　that　immune　checkpoint　inhibitors　lead　to　durable　responses　in　a　variety　of　cancers,　including　nasopharyngeal　carcinoma　(NPC),　however,　combination　approaches　(i.e.,　stereotactic　body　radiation　therapy,　SBRT)　are　required　to　extend　this　benefit　beyond　a　subset　of　patients.　This　study　retrospectively　evaluated　eight　recurrent/metastatic　NPC　patients,　to　investigate　how　radiation　could　potentiate　PD-1　checkpoint　inhibition　therapy.　Methods:　Between　September　2016　and　July　2017,　eight　consecutive　cases　with　histologically　confirmed　PDL1-positive　status,　for　which　prior　standard　therapy　had　been　ineffective　(five　patients),　were　treated　at　our　institution　and　Macao　Clinics　and　two　patients　had　disease　progression　within　6 months　of　completion　of　definitive　chemoradiation,　or　one　patient　refused　to　receive　chemoradiotherapy.　All　received　PD-1　inhibitors　first,　seven　of　them　accepted　SBRT　with　an　unmodified　PD-1　inhibitors　regimen　after　first　evaluation　as　they　were　unresponsive　to　PD-1　inhibitors　alone.　Treatment　was　discontinued　as　long　as　patients　were　experiencing　a　clinical　benefit　in　the　opinion　of　the　physicians　and　at　least　five　cycles　were　given　before　stoppage.　Results:　Median　follow-up　time　was　56.7 months.　The　confirmed　objective　response　rate　based　on　RECIST-v1.1　at　first　evaluation　was　12.5%　(1/8).　For　the　seven　cases　who　received　SBRT,　six　of　them　experience　an　objective　response　(6/7,　85.7%)　after　SBRT.　Only　one　patient　showed　rapid　progress　and　die　within　95 days　after　the　initiation　of　SBRT　intervention.　Three　patients　who　did　not　have　all　lesions　exposed　to　irradiation　were　available　to　evaluate　the　incidence　of　an　abscopal　effect,　however,　it　did　not　occur　as　expected.　Median　PFS　and　OS　for　the　seven　patients　were　8.0　and　30.8 months　after　SBRT　intervention,　respectively.　Two-year　OS　as　indicated　was　71.0%.　Conclusions:　PD-1　inhibitors　combined　with　SBRT　demonstrated　promising　antitumor　activity　in　patients　with　PD-L1　positive　RM-NPC.　Patients　may　benefit　from　continue　immunotherapy　beyond　disease　progression　when　SBRT　was　introduced.　©　2022,　The　Author(s).